Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

Clinical trial NCT04214067 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04214067
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Endometrial Endometrioid Adenocarcinoma Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

Start date: 2020-04-09
Primary completion: 2025-12-30
Enrollment: 164

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.